Rilzabrutinib (Wayrilz; Sanofi) may improve immune thrombocytopenia (ITP) outcomes, enable early intervention, and enhance patient quality of life.
Claude Sonnet 4.5 has emerged as the best-performing model in ‘risky tasks’, narrowly edging out GPT-5 in early evaluations ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback